Keywords
Inhibidores de Tirosin kinasa
Leucemia Linfocítica Crónica
Linfoma de Células del Manto
How to Cite
Abstract
Ibrutinib is an antineoplastic drug indicated for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. The therapeutic activity of ibrutinib is exerted by a highly specific reduction in the activity of Bruton's tyrosine kinase, a key player in the progression of certain tumors. Here we report the bioequivalence study of Binap®, a new formulation of ibrutinib 140 mg, manufactured by Laboratorio Varifarma S.A., with respect to the reference product Imbruvica® 140 mg, manufactured by Janssen Cilag Farmaceutica S.A. The clinical trial consisted of an open-label single administration of a 140 mg dose of ibrutinib, under fasting conditions, in 36 healthy male volunteers. A two-sequence, four-period (2 x 4) crossover replicate design was followed,with a 7-day washout period between each treatment period. Ibrutinib plasma concentration was quantified by means of a validated bioanalytical methodology using high performance liquid chromatography coupled to a tandem triple quadrupole mass spectrometry detector (HPLC-MS / MS). The results obtained in this study indicate that when a single 140 mg dose is administered to healthy subjects, both formulations show, on average, practically identical pharmacokinetic profiles. The pharmacokinetic parameters evaluated in this study were maximum plasma concentration (Cmax), area under the pharmacokinetic curve to the last sample obtained and extrapolated to infinity (AUC0-T and AUC0-∞), time to reach maximum plasma concentration (Tmax), elimination half life (T1/2) and elimination constant (Kel). The statistical data analysis for demonstration of bioequivalence was conducted on Cmax, AUC0-T and AUC0-∞, according to national and international bioequivalence regulations, with a confidence interval of 90% (CI90%). The analysis of variance test (ANOVA) with logarithmically transformed data shows a similar intra-subject CV for both products, 60% for Cmax and 46% for AUC0-T. For the parameter AUC0-T the point estimate is 96.4% (IC90% from 85.4 to 108.9%), for AUC0-∞ the point estimate is 99.4% (IC90% from 88.7 to 111, 4%), both within the pre-established bioequivalence range of 80-125%, and for Cmax the point estimate is 85.1% (IC90% from 72.2 to 100.2%), contained within the expanded bioequivalence range of 69.8-143.2%, according to the intra-subject CV obtained (> 50%). The results of this study indicate that Binap® (ibrutinib 140 mg) manufactured by Laboratorios Varifarma S.A. is bioequivalent to Imbruvica® 140 mg from Janssen Cilag S.A., therefore both products may be considered interchangeable in medical practice.
References
2. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075-13080. doi:10.1073/pnas.1004594107
3. Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015;75(1):111-121. doi:10.1007/s00280-014-2617-3
4. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 205552Orig2s000 MEDICAL REVIEW(S). Accessed July 27, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205552Orig2s000MedR.pdf
5. Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Ibrutinib. Accessed July 27, 2020. https://www.ema.europa.eu/en/documents/assessment-report/imbruvica-epar-public-assessment-report_en.pdf
6. de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015;75(5):907-916. doi:10.1007/s00280-015-2708-9
7. Davit B, Braddy AC, Conner DP, Yu LX. International guidelines for bioequivalence of systemically available orally administered generic drug products: A survey of similarities and differences. AAPS J. 2013;15(4):974-990. doi:10.1208/s12248-013-9499-x
8. Tothfalusi L, Endrenyi L. Sample sizes for designing bioequivalence studies for highly variable drugs. J Pharm Pharm Sci. 2011;15(1):73-84. doi:10.18433/j3z88f
9. Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001;28(2):155-169. doi:10.1023/A:1011503032353
10. Janssen Research & Development L. PCI-32765 (ibrutinib) Clinical Study Report PCI-32765CLL1001. 2013;32765.
11. Fda, Cder. Bioanalytical Method Validation Guidance for Industry Biopharmaceutics.; 2018. Accessed August 10, 2020. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
12. ANMAT. Disposición 12704/16. Accessed August 10, 2020. http://www.anmat.gov.ar/boletin_anmat/Noviembre_2016/Dispo_12704-16.pdf
13. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015;3(4). doi:10.1002/prp2.156
14. de Jong J, Haddish-Berhane N, Hellemans P, Jiao J, Sukbuntherng J, Ouellet D. The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure. Cancer Chemother Pharmacol. 2018;82(2):299-308. doi:10.1007/s00280-018-3613-9
15. Goods Administration T. AusPAR Attachment 2 Extract from the Clinical Evaluation Report for Ibrutinib About the Therapeutic Goods Administration (TGA).; 2016. Accessed July 27, 2020. https://www.tga.gov.au
16. O’Brien S, Furman RR, Fowler N, et al. The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study. Blood. 2013;122(21):4163-4163. doi:10.1182/blood.v122.21.4163.4163
17. Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132(21):2249-2259. doi:10.1182/blood-2018-06-860593
18. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210563Orig1s000 210563Orig2s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S). Accessed July 27, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210563Orig1s000,210563Orig2s000ClinPharmR.pdf
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar